Revance Securities Settlement
Not yet determinable; depends on number of valid claims submitted
What happened
Revance Therapeutics and its executives made material misrepresentations and omissions regarding the company's relationship with Teoxane SA and the tender offer and merger transaction with Crown Laboratories, Inc., allegedly violating federal securities laws. Defendants deny any wrongdoing or liability.
Do you qualify?
Anyone who purchased or acquired Revance Therapeutics common stock (ticker "RVNC") or 1.75% fixed coupon Convertible Senior Unsecured Notes between February 29, 2024 through the close of the merger on February 6, 2025, inclusive.
How to file
File a Proof of Claim and Release Form by August 28, 2026, either by mail (postmarked by deadline) or online. You must provide documentation of your purchase or acquisition of Revance securities.
In the news
- ALERT: Revance Therapeutics, Inc. Investors with Significant Losses Have Opportunity to Lead Class Action Lawsuit - RVNCYahoo Entertainment · December 31, 2021
- Kessler Topaz Meltzer & Check, LLP: Important Deadline Reminder for Revance Therapeutics, Inc. Investors in Securities Fraud Class Action LawsuitYahoo Entertainment · December 30, 2021
- Revance Therapeutics, Inc. Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More InformationYahoo Entertainment · December 30, 2021
- RVNC DEADLINE REMINDER: Kessler Topaz Meltzer & Check, LLP - Important LP February 8, 2022 Deadline Reminder for Revance Therapeutics, Inc.Yahoo Entertainment · December 25, 2021
Headlines via NewsAPI. ClaimWatch isn't affiliated with these publications.
New to class actions?
This summary was generated from public settlement documents and may contain errors. Confirm eligibility, deadlines, and payment terms on the official settlement website before filing. ClaimWatch is not a law firm and this is not legal advice. Filing a claim is free.
More securities settlements
View all →Tattooed Chef Securities Settlement
Tattooed Chef, Inc. faced a securities lawsuit alleging that purchasers of the company's common stock were damaged. The defendant has agreed to settle all claims in the action for $4,750,000 in cash without admitting wrongdoing.
Estée Lauder Securities Settlement
Estée Lauder is settling securities litigation relating to alleged damages to investors who purchased or acquired publicly traded common stock of The Estée Lauder Companies Inc. during the class period. The defendant has not admitted wrongdoing in this settlement.
E-Commerce China Dangdang Securities Settlement
E-Commerce China Dangdang, Inc. was involved in a take-private transaction (merger) that closed on September 20, 2016. Shareholders who held American Depositary Shares during the Class Period claim they were harmed by undisclosed information related to the Company's take-private transaction. The defendant has agreed to settle these securities claims without admitting wrongdoing.
Evolv Technologies Holdings Securities Settlement
Investors purchased publicly traded common stock of Evolv Technologies Holdings Inc. during a specific period and are entitled to compensation from a securities class action settlement. The page does not explicitly state what wrongdoing Evolv allegedly committed.